Wednesday, November 19, 2025 8:46:12 AM
$NWBO Northwest Biotherapeutics has submitted a Marketing Authorization Application (MAA) to the MHRA for DCVax®-L, an immunotherapy for glioblastoma. The MHRA are unable to comment on applications during the process of review, but the MHRA can CONFIRM that this application is NOT AFFECTED BY ANY BACKLOGS.
Here we go again with the BIZARRE “confirmation” that the delay in reviewing the DCVAX-l MAA IS NOT AFFECTED BY ANY BACKLOGS.
This is code for it’s NOT our fault. meaning something about the MAA status CHANGED between 12/11/2023 & 3/31/2025.
Bears will say the MAA was one of the few with major issues referred to CHM
Bulls will say that the MAA was modified to include something positive like Flaskworks, ORBIS, or agnostic.
I actually lean towards the former but in light of the advent news, Dr ashkan’s 2 month estimate, and GZ’s email to Lefty49 on IHUB, I still believe the MAA will be approved this year. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176939596
Here we go again with the BIZARRE “confirmation” that the delay in reviewing the DCVAX-l MAA IS NOT AFFECTED BY ANY BACKLOGS.
This is code for it’s NOT our fault. meaning something about the MAA status CHANGED between 12/11/2023 & 3/31/2025.
Bears will say the MAA was one of the few with major issues referred to CHM
Bulls will say that the MAA was modified to include something positive like Flaskworks, ORBIS, or agnostic.
I actually lean towards the former but in light of the advent news, Dr ashkan’s 2 month estimate, and GZ’s email to Lefty49 on IHUB, I still believe the MAA will be approved this year. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176939596
Bullish
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
